 SunTrust Banks upgraded shares of Momenta Pharmaceuticals NASDAQ:MNTA to a buy rating in a research note released on Thursday, LiveTradingNews reports. SunTrust Banks also issued estimates for Momenta Pharmaceuticals FY2022 earnings at 1.64 EPS, FY2023 earnings at 1.37 EPS and FY2024 earnings at 0.81 EPS. MNTA has been the topic of a number of other ... 